Michael Silverberg to Drug Therapy, Combination
This is a "connection" page, showing publications Michael Silverberg has written about Drug Therapy, Combination.
Connection Strength
0.280
-
Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014 Jan; 9(1):34-40.
Score: 0.113
-
Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
Score: 0.089
-
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
Score: 0.046
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.020
-
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
Score: 0.012